The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome

The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here?

(2013) William J. Sandborn   DIGESTIVE DISEASES

Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease

(2012) P. B. Allen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2012) Stephen J Halpin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biomarkers in Diverticular Diseases of the Colon

(2012) Antonio Tursi   DIGESTIVE DISEASES

Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease

(2012) Geert D'Haens et al.   GASTROENTEROLOGY

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

(2012) Geert DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum

(2012) Eva Klingberg et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Gender Role in Irritable Bowel Syndrome: A Comparison of Irritable Bowel Syndrome Module (ROME III) Between Male and Female Patients

(2012) Sanam Javid Anbardan et al.   Journal of Neurogastroenterology and Motility

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

(2011) Laurent Peyrin-Biroulet et al.   GUT

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease

(2011) Laurent Peyrin-Biroulet et al.   GUT

Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome

(2011) K. Hod et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?

(2010) John Keohane et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Short CDAI: Development and validation of a shortened and simplified Crohnʼs disease activity index

(2010) Kelvin Thia et al.   INFLAMMATORY BOWEL DISEASES

Development of the Crohnʼs disease digestive damage score, the Lémann score

(2010) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale

(2009) B. SPIEGEL et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease

(2008) Kelvin T. Thia et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

(2008) M Henriksen et al.   GUT

Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohnʼs disease

(2008) Taina Sipponen et al.   INFLAMMATORY BOWEL DISEASES

Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findings

(2007) Taina Sipponen et al.   INFLAMMATORY BOWEL DISEASES